Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

IMITREX 20 MG

SUMATRIPTAN (SUMATRIPTAN HEMISULFATE) : 20 MG · DIN 02230420 · GLAXOSMITHKLINE INC

Health Canada status: MARKETED

What is IMITREX?

IMITREX 20 MG contains SUMATRIPTAN (SUMATRIPTAN HEMISULFATE) : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02230420, held by GLAXOSMITHKLINE INC, supplied as SPRAY for NASAL administration. Health Canada currently lists it as marketed, status dated 22-Mar-2002. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What else is IMITREX called?

The same molecule, SUMATRIPTAN, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
ROSEMIGLatinCzechia
ImigranLatinAustralia, Bahrain, Czechia, Morocco, Saudi Arabia
Sumatriptan BluefishLatinSweden
Sumatriptan ViatrisLatinCzechia, Sweden
ROSEMIG SPRINTABLatinCzechia
Sumatriptan AccordLatinSweden
Arrow SumatriptanLatinSouth Africa
Imigran®LatinSweden
SumoreLatinSweden
TriptamLatinSouth Africa
APO-SumatriptanLatinAustralia
DamigraLatinNorway
FRIMIGLatinCzechia
Imigran InjectionLatinHungary, South Africa
IptamLatinAustralia

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

Product details and regulatory record

DIN02230420
Brand nameIMITREX
Generic / active ingredientSUMATRIPTAN (SUMATRIPTAN HEMISULFATE) : 20 MG
ManufacturerGLAXOSMITHKLINE INC
Strength20 MG
Dosage formSPRAY
Route of administrationNASAL
SchedulePrescription
ATC codeN02CC01 SUMATRIPTAN
AHFS class88:29.00* ; See footnote
BiosimilarNo
Health Canada statusMARKETED
Status date22-Mar-2002
Original market date1997-04-01 00:00:00

How is this product identified?

Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.

DIN (8-digit, as used in Nexara ordering)02230420
DIN (unpadded, as printed on some documents)2230420
Brand nameIMITREX
Active ingredient / INNSUMATRIPTAN (SUMATRIPTAN HEMISULFATE) : 20 MG
ATC codeN02CC01
ATC anatomical main groupN — Nervous system
ATC therapeutic subgroupN02
AHFS class88:29.00* ; See footnote
Health Canada schedulePrescription
Biosimilar biologicNo
Market authorization holderGLAXOSMITHKLINE INC

Health Canada approved product monograph (PDF)

Which pack is which?

Strength on the label20 MG
Dosage formSPRAY
RouteNASAL

One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Confirm the pack and get a price

Is SUMATRIPTAN in shortage in Canada?

A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.

Check availability for IMITREX

What can be used instead?

Other Canadian products sharing ATC code N02CC01 SUMATRIPTAN. 32 of 80 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
APO-SUMATRIPTAN100 MGTABLETAPOTEX INCMARKETEDDIN 02268396
APO-SUMATRIPTAN50 MGTABLETAPOTEX INCMARKETEDDIN 02268388
IMITREX5 MGSPRAYGLAXOSMITHKLINE INCMARKETEDDIN 02230418
IMITREX6 MG / 0.5 MLSOLUTIONGLAXOSMITHKLINE INCMARKETEDDIN 02212188
IMITREX DF - TAB 100MG100 MGTABLETGLAXOSMITHKLINE INCMARKETEDDIN 02212161
JAMP SUMATRIPTAN100 MGTABLETJAMP PHARMA CORPORATIONMARKETEDDIN 02545365
JAMP SUMATRIPTAN25 MGTABLETJAMP PHARMA CORPORATIONMARKETEDDIN 02545349
JAMP SUMATRIPTAN50 MGTABLETJAMP PHARMA CORPORATIONMARKETEDDIN 02545357
JAMP SUMATRIPTAN DF100 MGTABLETJAMP PHARMA CORPORATIONMARKETEDDIN 02545314
JAMP SUMATRIPTAN DF25 MGTABLETJAMP PHARMA CORPORATIONMARKETEDDIN 02545292

Who else supplies SUMATRIPTAN worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. SUMATRIPTAN appears in 269 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How much does SUMATRIPTAN cost around the world?

SUMATRIPTAN is listed on 18 national price registers Nexara tracks, across 206 pack listings published on 16 different price bases. What each country publishes is set out below.

MarketWhat that country publishesBrands listedPack listingsAs of
SwedenAIP (pharmacy purchase price)92903 Sep 2026
Czechiamax producer price (ex-factory)72503 Sep 2026
United Statesacquisition42303 Sep 2026
Italyprezzo al pubblico (classe A)112102 Sep 2026
Saudi Arabiapublic121701 Sep 2026
South Africasingle exit price121701 Sep 2026
Australiaex-manufacturer101308 Sep 2026
Luxembourgreimbursement131305 Sep 2026
Hungaryproducer price (ex-factory)111203 Sep 2026
Greeceproducer price (ex-factory)111103 Sep 2026
Romaniamax producer price7803 Sep 2026
AustriaKVP (Kassenverkaufspreis)3603 Sep 2026
United Kingdomhospital3331 Aug 2026
Norwaymax AUP (pharmacy retail)2307 Sep 2026
SpainPVP con IVA (public price)2205 Sep 2026
Belgiumpublic1101 Sep 2026
Bahrainretail (max)1101 Sep 2026
MoroccoPPV (public price)1105 Sep 2026

Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.

Ask Nexara for a landed Canadian price

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for IMITREX

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02230420. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.